Axial Therapeutics to Present at Upcoming Conferences
05 janv. 2024 08h05 HE
|
Axial Therapeutics
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological...
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
26 sept. 2023 08h00 HE
|
Axial Therapeutics
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
20 juin 2023 08h00 HE
|
Axial Therapeutics
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in PD– –IND-enabling...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
04 avr. 2023 08h00 HE
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
29 mars 2023 08h00 HE
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
01 nov. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
11 oct. 2022 08h00 HE
|
Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
Axial Therapeutics to Present at BioJapan Conference
06 oct. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference
13 sept. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...